Search
Close this search box.

Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - a Phase II Clinical Trial

Surgery is the standard treatment for primary kidney cancer, however, in some cases surgery is either not possible or other health problems make surgery high risk. This study involves a relatively new, highly precise multidirectional radiotherapy technique called Stereotactic Ablative Body Radiotherapy (SABR) and all participants will receive this radiotherapy technique. The aim of the study is to test the ability of this technique to control the cancer within the kidney for those people where surgery is not an option, as well as to examine the side effects of the treatment, including how it may affect your kidney’s function.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Final Accrual

71

Closing Date of Accrual

2nd March 2020

Trial Chairperson

A/Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC

Trial Contact

FASTRACKII@trog.com.au

Clinical Trial Registration

Related Post

TOPGEAR trial results published in the New England Journal of Medicine
18 September, 2024

TOPGEAR trial findings published in NEJM

18 September 2024: We’re thrilled to announce the release

11 September, 2024

Putting radiation medicine research on the world stage: 2024 ASM a resounding success

11 September 2024: Our 2024 Annual Scientific Meeting was